Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO1991014463 - PROCEDE D'ADMINISTRATION TRANSCUTANEE D'UNE SUBSTANCE MEDICAMENTEUSE ET DISPOSITIF A CET EFFET

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

WHAT IS CLAIMED IS:
1. A method of increasing the adhesiveness of a shaped, drug containing pressure sensitive adhesive composition, comprising adding an adhesiveness increasing amount of a clay to said adhesive prior to casting of the adhesive, the clay constituting up to 20% by weight of the composition.
2. The method of Claim 1, in which the drug constitutes less than 10% by weight of the composition.
3. The method of Claim 2, in which the clay is selected from the group consisting of hydrated aluminum silicate, kaolinite, montmorillonite, atapulgite, illite, bentonite, and halloysite.
4. The method of Claim 3, in which the clay is bentonite.
5. The method of Claim 2, in which the clay is present in an amount of less than about 5 to 6% by weight of the composition.
6. The method of Claim 5, in which the clay is present in an amount of about 5 to 6% by weight of the composition.
7. A dermal composition comprising a mixture of a drug, a pressure sensitive adhesive, a liquid solvent for one or more of the components of the composition and less than about 20% by weight of the total composition of an adhesiveness increasing amount of a clay. '
8. The composition of Claim 7, in which the clay is selected from the group consisting of hydrated aluminum silicate, kaolinite, montmorillonite, atapulgite, illite, bentonite, and halloysite.
9. The composition of Claim 8 which comprises a drug, a multipolymer containing vinyl acetate and ethylene monomers and including an acrylic polymer, a natural or synthetic rubber, a glycol, and a clay.
10. The composition of Claim 9 in which the clay is bentonite.
11. A composition of Claim 7 comprising 17-beta-estradiol, a pressure sensitive adhesive, a lower molecular weight glycol and an adhesiveness increasing amount of clay.
12. The transdermal drug delivery device of Claim 11 comprising an adhesiveness increasing effective amount of bentonite.
13. The composition of Claim 7, comprising 17-beta-estradiol, a multipolymer containing an acrylate and ethylene vinyl acetate monomers, a natural or synthetic rubber and a clay.
14. The composition of Claim 13 in which the clay is selected from the group consisting of hydrated aluminum silicate, kaolinite, montmorillonite, atapulgite, illite, bentonite, and halloysite.
15. The composition of Claim 14, additionally comprising a solvent for the 17-beta-estradoli .
16. The composition of Claim 13, which comprises as approximate percent by weight, 0.5 to 50% of the drug, 10 to 90% of the multipolymer, 2% to 20% of a rubber, 0.5 to 20% of a clay and 0.5 to 10% of a solvent for the drug.

17. The composition of Claim 16 which comprises about 0.5% to 6% of a clay.
18. A multi-phase dermal composition comprising a first phase comprising a pressure sensitive adhesive and in admixture therewith, one or more additional phases containing a polymer, a drug, a solvent for one or more of the components of the composition and a clay.
19. The composition of Claim 18, in which the clay is selected from the group consisting of hydrated aluminum silicate, kaolinite, montmorillonite, atapulgite, illite, bentonite, and halloysite.
20. The composition of Claim 19 which comprises a drug, a multipolymer containing vinyl acetate and ethylene monomers, an acrylic polymer, a natural or synthetic rubber and a glycol .
21. The composition of Claim 19, in which the clay is bentonite.
22. The composition of Claim 19 in which the clay is present in an amount of from about 0.5 to 20% by weight.
23. The composition of Claim 22 in which the clay is present in an amount of from about 0.5 to 6% by weight.
24. The composition of Claim 19, in which the drug is 17-beta-estradiol.
25. The composition of Claim 20, in which the drug is 17-beta-estradiol.
26. The composition of Claim 21, in which the drug is 17-beta-estradiol.
27. The composition of Claim 22, in which the drug is 17-beta-estradiol.

28. The composition of Claim 23, in which the drug is 17-beta-estradiol.